Blood Pressure

OCT 1, 2026 · JOURNAL ARTICLE

Hypertension epidemiology and primary care indicators in Portugal: a contemporary nationwide analysis

Blood Pressure

BACKGROUND: Hypertension remains a leading contributor to cardiovascular mortality worldwide. However, integrated surveillance frameworks linking epidemiological burden, healthcare

SEP 2, 2026 · JOURNAL ARTICLE

Characteristics of post-exercise responders versus non-responders following aerobic or isometric exercise in physically inactive adults of African and South Asian descent with high-normal blood pressure or grade I hypertension.

Blood Pressure

A rigorous randomised crossover trial in a specific population demonstrating a mechanistic characterisation of responders to aerobic exercise, but limited by modest sample size, surrogate endpoints (arterial stiffness, autonomic parameters), and lack of long-term clinical outcome data.

AUG 10, 2026 · JOURNAL ARTICLE

Self-reported health status and blood pressure medication use among persons living with hypertension in Kenya.

Blood Pressure

Cross-sectional analysis of survey data identifying associations between self-reported health and medication use, without causal inference or intervention testing; descriptive of a real-world population but subject to confounding and reverse causation.

AUG 6, 2026 · JOURNAL ARTICLE

Association of air pollutant levels and blood pressure variability in patients with essential hypertension: a distributed lag analysis study.

Blood Pressure

Observational study with adequate sample size demonstrating associations between multiple air pollutants and blood pressure variability in hypertensive patients, but lacks a comparator group and causal design.

AUG 6, 2026 · JOURNAL ARTICLE

Lifestyle modifications in individuals with blood pressure beyond treatment target despite pharmacological treatment: design and baseline characteristics of the MeDiPA randomised controlled trial.

Blood Pressure

This is a design paper reporting baseline characteristics of a small RCT (n=66) not yet reporting efficacy outcomes; the trial will generate evidence but no treatment effect data are presented.